A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: The PRESTO study

Archives of Neurology

Volumn 62, Issue 2, 2005, Pages 241-248

  Schwid, Steven R ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; RASAGILINE;

ADULT; AGED; ANOREXIA; ARTHRITIS; ARTICLE; BALANCE DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FREQUENCY ANALYSIS; HOME; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MELANOMA; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MULTICENTER STUDY; PARKINSON DISEASE; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STROKE; TREATMENT OUTCOME; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; ANOREXIA; ANTIPARKINSON AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDANS; LEVODOPA; MALE; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; MOTOR ACTIVITY; PARKINSON DISEASE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; VOMITING; WEIGHT LOSS;

EID: 13444302612     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.62.2.241     Document Type: Article

References (29)

1. Ahlskog JE. Medical treatment of later-stage motor problems of Parkinson's disease. Mayo Clin Proc. 1999;74:1239-1254.
2. Albin RI, Frey KA. Initial agonist treatment of Parkinson disease: a critique. Neurology. 2003;60:390-394.
3. Lees AJ, Shaw KM, Kohout LJ, et al. Deprenyl in Parkinson's disease. Lancet. 1977;2:791-795.
4. Schachter M, Marsden CD, Parkes JD, Jenner P, Testa B. Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa. J Neurol Neurosurg Psychiatry. 1980;43:1016-1021.
5. Heinonen EH, Rinne UK, Tuominen J. Selegiline in the treatment of daily fluctuations in disability of parkinsonian patients with long-term levodopa treatment. Acta Neurol Scand Suppl. 1989;126:113-118.
6. Golbe LI, Lieberman AN, Muenter MD, et al. Deprenyl in the treatment of symptom fluctuation in advanced Parkinson's disease. Clin Neuropharmacol. 1988;11:45-55.
7. Ulm G, Fornadi F. R-(-)-deprenyl in the treatment of end-of-dose akinesia. J Neural Transm Suppl. 1987;25:163-172.
8. Yahr MD, Elizan TS, Moros D. Selegiline in the treatment of Parkinson's disease: long term experience. Acta Neurol Scand Suppl. 1989;126:157-161.
9. Hubble JP, Koller WC, Waters C. Effect of selegiline dosing on motor fluctuations in Parkinson's disease. Clin Neuropharmacol. 1993;16:83-87.
10. Sterling J, Veinberg A, Lerner D, et al. (R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B. J Neural Transm Suppl. 1998;52:301-305.
11. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59:1937-1943.
12. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004;61:561-566.
13. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427-442.
14. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of subjects for the clinician. J Psychiatr Res. 1975;12:189-198.
15. Beck AT. Beck Depression Inventory. San Antonio, Tex: Psychological Corp; 1987.
16. Moller H, Mellemkjaer L, McLaughlin JK, Olsen JH. Occurrence of different cancers in patients with Parkinson's disease. BMJ. 1995;310:1500-1501.
17. Vanacore N, Spila-Alegiani S, Raschetti R, Meco G. Mortality cancer risk in parkinsonian patients: a population-based study. Neurology. 1999;52:395-398.
18. Fahn S, Elton RL; Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CO, Calne DB, Goldstein M, eds. Recent Development in Parkinson's Disease. Vol 2. Florham Park, NJ: Macmillan Health Care Information; 1987:153-164.
19. Welsh M, McDermott MP, Holloway RG, et al; Parkinson Study Group. Development and testing of the Parkinson's disease quality of life scale. Mov Disord. 2003;18;637-645.
20. Schwab RS, England AC Jr. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FJ, Donaldson IML, eds. Third Symposium on Parkinson's Disease, Held at the Royal College of Surgeons of Edinburgh on 20, 21 and 22 May 1968. Edinburgh, Scotland: E & S Livingstone; 1969:152-157.
21. Hochberg Y. A sharper Bonferroni procedure for multiple significance testing. Biometrika. 1988;75:800-802.
22. Marcus R, Peritz E, Gabriel KR. On closed testing procedures with special reference to ordered analysis of variance. Biometrika. 1976;63:655-660.
23. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol. 1997;42:747-755.
24. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord. 1994;9:40-47.
25. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997;49:162-168.
26. Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Neurology. 1998;51:1057-1062.
27. Korczyn AD, Nussbaum M. Emerging therapies in the pharmacological treatment of Parkinson's disease. Drugs. 2002;62:775-786.
28. Gotz ME, Breithaupt W, Sautter J, et al. Chronic TVP-1012 (rasagiline) dose-activity response of monoamine oxidases A and B in the brain of the common marmoset. J Neural Transm Suppl. 1998;52:271-278.
29. Finberg JP, Takeshima T, Johnston JM, Commissiong JW. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuroreport. 1998;9:703-707.